Last reviewed · How we verify

Sivextro 200 milligrams Oral Tablet

Fundacion Clinic per a la Recerca Biomédica · FDA-approved active Small molecule

Sivextro 200 milligrams Oral Tablet is a Oxazolidinone antibiotic Small molecule drug developed by Fundacion Clinic per a la Recerca Biomédica. It is currently FDA-approved for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).

Sivextro (tedizolid) inhibits bacterial protein synthesis by binding to the bacterial ribosome.

Sivextro (tedizolid) inhibits bacterial protein synthesis by binding to the bacterial ribosome. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).

At a glance

Generic nameSivextro 200 milligrams Oral Tablet
SponsorFundacion Clinic per a la Recerca Biomédica
Drug classOxazolidinone antibiotic
TargetBacterial 70S ribosome (peptidyl transferase center)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Tedizolid is an oxazolidinone antibiotic that binds to the bacterial 70S ribosome and inhibits peptidyl transferase, preventing peptide bond formation and halting protein synthesis. This bacteriostatic mechanism is effective against a broad spectrum of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sivextro 200 milligrams Oral Tablet

What is Sivextro 200 milligrams Oral Tablet?

Sivextro 200 milligrams Oral Tablet is a Oxazolidinone antibiotic drug developed by Fundacion Clinic per a la Recerca Biomédica, indicated for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).

How does Sivextro 200 milligrams Oral Tablet work?

Sivextro (tedizolid) inhibits bacterial protein synthesis by binding to the bacterial ribosome.

What is Sivextro 200 milligrams Oral Tablet used for?

Sivextro 200 milligrams Oral Tablet is indicated for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).

Who makes Sivextro 200 milligrams Oral Tablet?

Sivextro 200 milligrams Oral Tablet is developed and marketed by Fundacion Clinic per a la Recerca Biomédica (see full Fundacion Clinic per a la Recerca Biomédica pipeline at /company/fundacion-clinic-per-a-la-recerca-biom-dica).

What drug class is Sivextro 200 milligrams Oral Tablet in?

Sivextro 200 milligrams Oral Tablet belongs to the Oxazolidinone antibiotic class. See all Oxazolidinone antibiotic drugs at /class/oxazolidinone-antibiotic.

What development phase is Sivextro 200 milligrams Oral Tablet in?

Sivextro 200 milligrams Oral Tablet is FDA-approved (marketed).

What are the side effects of Sivextro 200 milligrams Oral Tablet?

Common side effects of Sivextro 200 milligrams Oral Tablet include Nausea, Headache, Diarrhea, Vomiting, Peripheral neuropathy, Optic neuropathy.

What does Sivextro 200 milligrams Oral Tablet target?

Sivextro 200 milligrams Oral Tablet targets Bacterial 70S ribosome (peptidyl transferase center) and is a Oxazolidinone antibiotic.

Related